

WuXi STA launches first parenteral formulation manufacturing line in China

24 January 2022 | News

WuXi STA's drug product platform covers a full range of services for a broad range of oral and injectable dosage forms



WuXi STA, a subsidiary of WuXi AppTec, has announced that its first parenteral formulation manufacturing line at the Wuxi city site in China is now in commission. This wholly automatic sterile manufacturing line operates in a full isolation system with an annual capacity of 2 million units.

The industry-leading automatic parenteral filling line features multiple filling modules and a built-in lyophilizer to fill vials, syringes, and cartridges of a full range of sizes, as well as to produce lyophilized powders. Different filling modules can be switched rapidly, allowing for maximum flexibility and production efficiency.

This new parenteral formulation manufacturing line and the sterile manufacturing plant at Wuxi city site are designed per cGMP requirements by U.S. FDA, EMA, and China NMPA, equipped with the industry latest generation of isolation system and filling machine. The entire filling process is performed by robotics in a full isolation system, designed to minimize human interventions and eliminate contaminations to ensure high product quality.

In addition to the launch of this parenteral formulation manufacturing line, a second sterile filling line with an annual capacity of 10 million units is scheduled to start operation in Q3 this year at the same site.